• Molecular NameProguanil
  • SynonymNA
  • Weight253.737
  • Drugbank_IDDB01131
  • ACS_NO500-92-5
  • Show 2D model
  • LogP (experiment)2.53
  • LogP (predicted, AB/LogP v2.0)1.71
  • pkapKa2.3, 10.4 (22.5°)
  • LogD (pH=7, predicted)-1.34
  • Solubility (experiment)0.156 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.49
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.14
  • No.of HBond Donors5
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA88.79
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA prophylactic antimalarial drug.
  • Absorption_valueN/A
  • Absorption (description)Rapidly and well absorbed in humans following oral doses ranging from 50 to 500 mg.
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding75.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmVariably metabolized in the liver by cytochrome P450 isoenzymes to the active triazine metabolite, cycloguanil. This variable metabolism of proguanil may have profound clinical importance in poor metabolizers such as the Asian and African populations at risk for malaria infection. Prophylaxis with proguanil may not be effective in these persons because they may not achieve adequate therapeutic levels of the active compound, cycloguanil, even after multiple doses.
  • Half life20 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A